24/7 Market News Snapshot 29 August, 2024 – Gain Therapeutics, Inc. Common Stock (NASDAQ:GANX)

August 29, 2024

DENVER, Colo., 29 August, 2024 (247marketnews.com) – (NASDAQ:GANX) are discussed in this article.
Gain Therapeutics, Inc. (GANX) is experiencing a promising upward trend in the biotechnology sector, with pre-market trading at $1.404, reflecting a 4.78% increase from the previous close of $1.340. This positive movement is underscored by robust trading volume of 918.20K, indicating strong investor interest and sentiment. Technical indicators suggest a potential continuation of this bullish momentum, establishing GANX as an attractive opportunity for investors focused on growth in the biopharma landscape.

The company has recently announced encouraging results from its Phase 1 study of GT-02287, a groundbreaking therapeutic candidate designed to treat Parkinson’s disease, including cases associated with the GBA1 mutation. This study, which involved 72 healthy volunteers, evaluated the safety, tolerability, and pharmacokinetics of GT-02287 and yielded an impressive safety profile, with no serious adverse events reported. Both single and multiple doses were well tolerated, highlighting the treatment’s viability even at the highest dosages.

Data analysis revealed target engagement of GT-02287 in cerebrospinal fluid, suggesting its potential efficacy for neurodegenerative conditions. The favorable pharmacokinetic attributes observed bolster its promise as a leading treatment option for those affected by Parkinson’s disease. The company plans to initiate a Phase 1b trial focused on Parkinson’s patients in Q4 2024, aimed at further assessing GT-02287’s safety and tolerability while demonstrating proof of mechanism via biomarker signals.

Dr. Jonas Hannestad, Chief Medical Officer, expressed optimism regarding the study’s results, while interim CEO Gene Mack emphasized the significance of this data in advancing their important work in neurology. With its innovative approach, Gain Therapeutics remains committed to developing transformative therapies that have the potential to improve the lives of patients facing debilitating neurological disorders.

Related news for (GANX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.